Natixis Advisors, L.P. Halozyme Therapeutics, Inc. Transaction History

Natixis Advisors, L.P.

$54.1 Billion
Q1 2025

A detailed history of Natixis Advisors, L.P. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 143,745 shares of HALO stock, worth $8.96 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

143,745

Previous 119,434 20.36%

Holding current value

$8.96 Million

Previous $5.71 Million 60.63%

% of portfolio

0.02%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$47.74 - $65.16 $1.16 Million - $1.58 Million	24,311 Added 20.36%	143,745 $9.17 Million
Q4 2024 Feb 10, 2025	SELL	$42.57 - $61.09 $90,503 - $129,877	-2,126 Reduced 1.75%	119,434 $5.71 Million
Q3 2024 Nov 06, 2024	BUY	$51.3 - $64.42 $2.9 Million - $3.64 Million	56,461 Added 86.73%	121,560 $6.96 Million
Q2 2024 Aug 01, 2024	BUY	$37.81 - $52.4 $444,759 - $616,381	11,763 Added 22.05%	65,099 $3.41 Million
Q1 2024 Apr 25, 2024	BUY	$33.68 - $41.95 $505,604 - $629,753	15,012 Added 39.17%	53,336 $2.17 Million
Q4 2023 Feb 06, 2024	SELL	$33.32 - $42.1 $216,446 - $273,481	-6,496 Reduced 14.49%	38,324 $1.42 Million
Q3 2023 Nov 13, 2023	BUY	$36.46 - $44.03 $65,263 - $78,813	1,790 Added 4.16%	44,820 $1.71 Million
Q2 2023 Aug 15, 2023	BUY	$30.28 - $38.74 $413,473 - $528,994	13,655 Added 46.49%	43,030 $1.55 Million
Q1 2023 May 11, 2023	SELL	$32.86 - $55.7 $703,664 - $1.19 Million	-21,414 Reduced 42.16%	29,375 $1.12 Million
Q4 2022 Jan 27, 2023	BUY	$40.06 - $59.44 $325,727 - $483,306	8,131 Added 19.06%	50,789 $2.89 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $185,637 - $249,476	4,818 Added 12.73%	42,658 $1.69 Million
Q2 2022 Aug 12, 2022	BUY	$37.35 - $48.3 $284,644 - $368,094	7,621 Added 25.22%	37,840 $1.67 Million
Q1 2022 May 12, 2022	BUY	$31.97 - $41.06 $125,578 - $161,283	3,928 Added 14.94%	30,219 $1.21 Million
Q4 2021 Feb 08, 2022	SELL	$31.82 - $40.75 $115,474 - $147,881	-3,629 Reduced 12.13%	26,291 $1.06 Million
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $145,147 - $175,142	-3,773 Reduced 11.2%	29,920 $1.22 Million
Q2 2021 Aug 12, 2021	BUY	$38.84 - $51.31 $77,252 - $102,055	1,989 Added 6.27%	33,693 $1.53 Million
Q1 2021 May 05, 2021	BUY	$39.51 - $51.45 $328,407 - $427,652	8,312 Added 35.53%	31,704 $1.32 Million
Q4 2020 Feb 12, 2021	SELL	$25.81 - $43.62 $746,554 - $1.26 Million	-28,925 Reduced 55.29%	23,392 $999,000
Q3 2020 Nov 12, 2020	BUY	$25.74 - $29.63 $3,346 - $3,851	130 Added 0.25%	52,317 $1.38 Million
Q2 2020 Aug 11, 2020	BUY	$16.25 - $26.81 $848,038 - $1.4 Million	52,187 New	52,187 $1.4 Million

Others Institutions Holding HALO

# of Institutions

584

Shares Held

122M

Call Options Held

308K

Put Options Held

186K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.68B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Halozyme Therapeutics, Inc. Transaction History